The Hypothetical Impact of Accelerate Pheno (ACC) on Time to Effective Therapy and Time to Definitive Therapy for bloodstream infections due to drug-resistant Gram-negative bacilli.

BACKGROUND: Strategies are needed to improve time to optimal therapy in patients with bloodstream infections (BSI) due to resistant Gram-negative (GN) pathogens. Accelerate Pheno™ (ACC) can provide antimicrobial susceptibility results within 7 hours of a positive culture and may more rapidly optimize therapy.

OBJECTIVES: The primary objective was to evaluate the hypothetical impact of ACC on time to effective therapy (TTET) and time to definitive therapy (TTDT) among patients with BSI due to resistant GN pathogens.

METHODS: ACC was performed on resistant GN BSI isolates and results were not available to clinicians in real time. Potential benefit of having ACC on TTET or TTDT was determined if modifications to antimicrobial regimens could have been made sooner with ACC. Comparisons on the impact of ACC in the presence or absence of Verigene GN-BC were performed.

RESULTS: 61 patients with resistant GN BSI were evaluated. The median actual TTET and TTDT in the cohort was 25.9 hours (h) (interquartile (IQR) 18.5, 42.1) and 47.6 h (IQR 24.9, 79.6), respectively. Almost half of the patients had potential improvement in TTET and/or TTDT with ACC. In patients who would have had a benefit the median potential decreases in TTET and TTDT were 16.6 h (IQR 5.5 - 30.6) and 29.8 h (IQR 13.6 - 43), respectively. The largest potential improvements were seen in patients where Verigene results were not available.

CONCLUSIONS: Among patients with resistant GN BSI in a setting where other rapid diagnostic technologies are utilized, ACC results could have further improved TTET and TTDT.